Novartis is preparing to present new analyses and data for its multiple sclerosis drug Gilenya at the upcoming Joint ACTRIMS-ECTRIMS Meeting in Boston this month. Gilenya, an oral disease-modifying therapy (DMT), has been developed by Novartis for relapsing-remitting multiple sclerosis (RRMS). The drug works by targeting both focal and diffuse central nervous system damage. It prevents inflammation from occurring in the brain and defuses harmful cells inside the CNS. The company recently received positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the label expansion of Gilenya in RRMS in the EU.